Pfizer’s Xeljanz Approved by US FDA

Pfizer are celebrating today after US regulators approved their rheumatoid arthritis drug, Xeljanz, yesterday.  The treatment is the first Janus kinase (JAK) inhibitor to be approved for rheumatoid arthritis. The US Food and Drug Administration (FDA) have given the green light to Xeljanz (tofacitinib) 5mg twice-daily for the medication of adults with moderately to severely

Continue Reading